Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05496036
Title Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.